Article
Fycompa: Effective Treatment for Primary Generalized Tonic-Clonic Seizures
Author(s):
Treating patients suffering from primary generalized tonic-clonic (PGTC) seizures with once-daily 8mg doses of adjunctive perampanel (Fycompa/Eisai) can effectively control the seizures, recent study finds.
Treating patients suffering from primary generalized tonic-clonic (PGTC) seizures with once-daily 8 mg doses of adjunctive perampanel (Fycompa/Eisai) can effectively control the seizures, recent study finds.
Data from a phase III study conducted in the UK in 162 patients presented at the American Academy of Neurology’s 68th Annual meeting in Vancouver, Canada, show that a change in seizure frequency is greater in patients given perampanel rather than placebo.
According to Bernhard Steinhoff, Medical Director and Executive Chief Physician, Kork Epilepsy Centre, Germany, “These data confirm that adjunctive perampanel provides effective management of seizures in all groups of idiopathic generalized epilepsy (IGE) patients studied with PGTC.”
The post-hoc analysis of the phase III study showed similar median percent change from baseline in PGTC for age, sex, and ethnic groups.
Proven its efficacy, perampanel is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in adult and adolescent patients (at least 12 years of age) suffering from epilepsy along with IGE.
